- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: California Drug Price Transparency Bill Pulled
What we're reading, August 18, 2016: California drug price transparency bill gets pulled; researchers work on a new opioid painkiller without the addiction; and the need for more diversity in genetic sequencing.
A California senator has withdrawn his bill that would require drug makers explain steep price hikes. According to STAT, the bill was killed because amendments made last week had gutted the legislation and made it difficult to accomplish the goal of the bill. If passed, the bill would have required drug makers report price increases of more than 10% during any 12-month period and these price increases would have to be justified for medicines that had a list price of more than $10,000. The senator that first introduced the bill hopes to reintroduce it at a later point.
Researchers are trying to create a new opioid painkiller that does not cause addiction that leads to deadly overdoses. Scientists have discovered PZM21, a chemical that turns the opioid receptor on without negative effects, according to NPR. Testing has found mice had a pain reduction without seeming to get high. However, the researchers encourage that while the findings are encouraging, the compounds being worked on might not be the answer to the opioid epidemic.
Genetic testing may be more common, but the accuracy of these test results vary based on ethnicity. A new study found that there is a greater need for diversity in genomic research in order to interpret ethnic differences, reported Kaiser Health News. The New England Journal of Medicine published research that showed that even for new genomic data projects that have diverse populations there is still a need for data from Native Americans and Asian Americans.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
